Inspire Investing LLC Purchases Shares of 12,815 InMode Ltd. $INMD

Inspire Investing LLC acquired a new stake in shares of InMode Ltd. (NASDAQ:INMD) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,815 shares of the healthcare company’s stock, valued at approximately $185,000.

Other institutional investors have also recently bought and sold shares of the company. Parallel Advisors LLC boosted its stake in InMode by 63.1% in the second quarter. Parallel Advisors LLC now owns 1,973 shares of the healthcare company’s stock valued at $28,000 after acquiring an additional 763 shares during the last quarter. CWM LLC grew its position in InMode by 106.4% during the first quarter. CWM LLC now owns 2,369 shares of the healthcare company’s stock valued at $42,000 after acquiring an additional 1,221 shares during the last quarter. Summit Securities Group LLC purchased a new stake in InMode during the first quarter valued at about $70,000. Farther Finance Advisors LLC lifted its position in InMode by 302.3% in the second quarter. Farther Finance Advisors LLC now owns 8,110 shares of the healthcare company’s stock valued at $117,000 after purchasing an additional 6,094 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of InMode in the first quarter valued at about $182,000. Institutional investors own 68.04% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on INMD. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research report on Friday, October 10th. Zacks Research upgraded InMode from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of InMode in a research report on Wednesday, October 8th. Canaccord Genuity Group increased their price target on shares of InMode from $14.00 to $16.00 and gave the stock a “hold” rating in a research report on Friday, October 10th. Finally, Barclays dropped their price target on shares of InMode from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. One investment analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $16.85.

InMode Trading Up 0.6%

Shares of INMD opened at $15.31 on Friday. InMode Ltd. has a 12-month low of $13.14 and a 12-month high of $19.85. The company has a market capitalization of $967.75 million, a PE ratio of 6.20 and a beta of 2.09. The business’s 50 day moving average is $14.89 and its 200 day moving average is $14.68.

InMode (NASDAQ:INMD) last released its quarterly earnings data on Wednesday, July 30th. The healthcare company reported $0.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.03). InMode had a net margin of 44.50% and a return on equity of 18.38%. The company had revenue of $95.60 million for the quarter, compared to the consensus estimate of $98.45 million. During the same quarter in the previous year, the business earned $0.34 EPS. The company’s quarterly revenue was up 10.6% on a year-over-year basis. Equities research analysts predict that InMode Ltd. will post 1.75 earnings per share for the current year.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.